Literature DB >> 1708786

Targeted enzyme therapy of experimental glomerulonephritis in rats.

R B White1, L Lowrie, J E Stork, S S Iskandar, M E Lamm, S N Emancipator.   

Abstract

We sought to determine whether systemic administration of proteases ameliorates membranous nephritis induced in rats by immunization and challenge with cationic bovine gamma globulin, and whether targeting of protease to glomerular capillaries increases efficacy. Proteases substituted with biotin were targeted via the cationic protein avidin A, which by virtue of its charge has affinity for the glomerular basement membrane. Despite identical pretreatment proteinuria, rats given untargeted protease (biotin-conjugated without avidin, or unconjugated plus avidin) had significantly less proteinuria than saline-treated controls and nephrotic rats given avidin plus biotin-conjugated (targeted) protease had even less proteinuria and reduced glomerular rat IgG and C3. Among more severely nephrotic rats, targeted protease was again more effective than untargeted protease at reducing proteinuria, and also decreased the size of electron-dense glomerular deposits, hypercholesterolemia, and creatininemia. Inactivated targeted proteases had no effect on proteinuria, hypercholesterolemia, or azotemia. Finally, active targeted protease did not affect proteinuria in the nonimmune mediated nephrosis induced by puromycin aminonucleoside. We conclude that systemic protease can specifically diminish glomerular immune deposits, proteinuria, hyperlipidemia, and creatininemia associated with experimental immune complex glomerulonephritis but not toxic nephrosis, and that targeted protease is more effective than untargeted protease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1708786      PMCID: PMC295303          DOI: 10.1172/JCI115203

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  20 in total

1.  [In vivo degradation of immune complexes in the kidney by orally administered enzymes].

Authors:  C Steffen; J Menzel
Journal:  Wien Klin Wochenschr       Date:  1987-08-07       Impact factor: 1.704

2.  [High-dose gamma globulin therapy for membranous nephropathy, membranoproliferative glomerulonephritis and lupus nephritis].

Authors:  T Sugisaki; S Shiwachi; S Ito; M Yonekura; K Kitazawa; J Yamamoto; J Uchida; H Kawasumi; K Sato; T Shibata
Journal:  Nihon Jinzo Gakkai Shi       Date:  1983-06

3.  Removal of glomerular immune complex deposits by excess antigen in chronic mouse model of immune complex disease.

Authors:  A O Haakenstad; G E Striker; M Mannik
Journal:  Lab Invest       Date:  1983-03       Impact factor: 5.662

4.  The use of avidin-biotin interaction in immunoenzymatic techniques.

Authors:  J L Guesdon; T Ternynck; S Avrameas
Journal:  J Histochem Cytochem       Date:  1979-08       Impact factor: 2.479

5.  Enzymolysis of glomerular immune deposits in vivo with dextranase/protease ameliorates proteinuria, hematuria, and mesangial proliferation in murine experimental IgA nephropathy.

Authors:  L Gesualdo; S Ricanati; M O Hassan; S N Emancipator; M E Lamm
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

6.  Determinants of glomerular localization of subepithelial immune deposits: effects of altered antigen to antibody ratio, steroids, vasoactive amine antagonists, and aminonucleoside of puromycin on passive Heymann nephritis in rats.

Authors:  D J Salant; S Belok; M M Stilmant; C Darby; W G Couser
Journal:  Lab Invest       Date:  1979-07       Impact factor: 5.662

7.  Therapy of the idiopathic nephrotic syndrome with alternate day steroids.

Authors:  W K Bolton; N O Atuk; B C Sturgill; F B Westervelt
Journal:  Am J Med       Date:  1977-01       Impact factor: 4.965

8.  Dynamics of renal histamine in normal rat kidney and in nephrosis induced by aminonucleoside of puromycin.

Authors:  H E Abboud; S L Ou; J A Velosa; S V Shah; T P Dousa
Journal:  J Clin Invest       Date:  1982-02       Impact factor: 14.808

9.  A controlled study of short-term prednisone treatment in adults with membranous nephropathy.

Authors: 
Journal:  N Engl J Med       Date:  1979-12-13       Impact factor: 91.245

10.  Proteolytic enzyme treatment reduces glomerular immune deposits and proteinuria in passive Heymann nephritis.

Authors:  M Nakazawa; S N Emancipator; M E Lamm
Journal:  J Exp Med       Date:  1986-12-01       Impact factor: 14.307

View more
  4 in total

1.  Treatment of passively transferred experimental autoimmune myasthenia gravis using papain.

Authors:  K Poulas; T Tsouloufis; S J Tzartos
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

2.  Microbial IgA protease removes IgA immune complexes from mouse glomeruli in vivo: potential therapy for IgA nephropathy.

Authors:  Michael E Lamm; Steven N Emancipator; Janet K Robinson; Michifumi Yamashita; Hisashi Fujioka; Jiazhou Qiu; Andrew G Plaut
Journal:  Am J Pathol       Date:  2007-12-28       Impact factor: 4.307

3.  Bacterial IgA protease-mediated degradation of agIgA1 and agIgA1 immune complexes as a potential therapy for IgA Nephropathy.

Authors:  Li Wang; Xueying Li; Hongchun Shen; Nan Mao; Honglian Wang; Luke Cui; Yuan Cheng; Junming Fan
Journal:  Sci Rep       Date:  2016-08-03       Impact factor: 4.379

Review 4.  The Role of Proteases and Serpin Protease Inhibitors in β-Cell Biology and Diabetes.

Authors:  Yury Kryvalap; Jan Czyzyk
Journal:  Biomolecules       Date:  2022-01-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.